Tricida Inc

Tricida — Corporate Update (November 2022)

42 slides from Tricida's corporate update, Nov 17, 2022

  1. Slide 1: Summary of the Veverimer Opportunity Post-VALOR-CKD Data

    Summary of the Veverimer Opportunity Post-VALOR-CKD Data November 2022 Exhibit 99.1

  2. Slide 2: Forward Looking Statements

    2 Forward Looking Statements Any statements contained in this presentation that are not statements of historical facts are forward-looking statements as defined under the Federal securities laws. Forward-looking statements involve risks and uncertainties that could cause actual results to differ mat

  3. Slide 3: Market Overview

    Market Overview TRICIDA 3

  4. Slide 4: Kidney Disease Impacts Acid-Base Balance

    4 Daily Metabolism Kidney Disease Impacts Acid-Base Balance Which Is Critical to Maintain Normal Physiologic Function Kraut. Nat Rev Nephrol. 2010;6(5):274; KDIGO Clinical Practice Guidelines 2012. Diseased Kidneys Lose Capacity to Excrete Acid Acid is generated from dietary sources and daily metabo

  5. Slide 5: Persistent Acid Retention and Sustained Expression of ET-1, Aldosterone and Angiotensin II

    5 Laghmani K et al., J Clin Invest 107:1563-9, 2001. Wesson DE, J Am Soc Nephrol 12:1826-35, 2001. Wesson DE et al., Kidney Int 78:1128-35, 2010. Wesson DE et al., Kidney Int 82:1184-94, 2012. Wesson DE et al., Nephrol Dial Transplant 30:762-70, 2015. Phisitkul S et al., Kidney Int 77:617-23, 2010.

  6. Slide 6: Persistent Acid Retention Can Result in Serious Health Consequences

    6 Persistent Acid Retention Can Potentially Result in Serious Health Consequences Acid Buffering Leads to Increased Protein Catabolism Muscle Wasting, Reduced Physical Functioning Acid Buffering Leads to Loss of Bone Density Increased Risk of Fractures, Renal Osteodystrophy Reduced Renal Acid Secret

  7. Slide 7: No FDA-Approved Therapies to Slow CKD Progression Through Treating Metabolic Acidosis

    7 (Data on File) Despite the High Unmet Need, There Are No FDA-Approved Therapies to Slow CKD Progression Through the Treatment of Chronic Metabolic Acidosis *Represents patients with Stages 1-5 CKD and metabolic acidosis. Data on file: 2019 US Census data, USRDS 2020 Annual Report, KDIGO 2012, Inke

  8. Slide 8: Prevalence of Metabolic Acidosis in CKD and Patients Treated by Physician Type

    8 Prevalence of Metabolic Acidosis in Patients with CKD and Estimated Number of Patients Treated by Physician Type Nephrologist-treated patients Patients treated by all physicians involved in CKD care Estimated US population of patients with metabolic acidosis and CKD *Represents patients with Stage

  9. Slide 9: Veverimer Overview

    Veverimer Overview TRICIDA 2

  10. Slide 10: Veverimer Designed to Bind and Remove HCl with High Capacity and Selectivity

    10 Veverimer was Designed to Bind and Remove HCl with High Capacity and Selectivity GI: Gastrointestinal. HCl: Hydrochloric acid. Veverimer’s maximum theoretical HCl binding capacity is approximately 10 mEq/gram. Excreted, resulting in removal of HCl* Binds protons (H+) and then selectively binds ch

  11. Slide 11: Veverimer Developed to Bind and Remove Acid from the GI Tract

    11 Veverimer Was Developed to Bind and Remove Acid from the Gastrointestinal Tract Klaerner. J Pharmacol Exp Therapeutics. 2020;375:439 • Veverimer is a non-absorbed, low-swelling, spherical polymer bead ~100 micrometers in diameter − Each bead is a single, high molecular weight, crosslinked polyami

  12. Slide 12: Veverimer Unlikely to Have Significant Drug-Drug Interactions

    12 Veverimer Is Unlikely to Have Significant Drug-Drug Interactions Parsell. Drug Metab Dispos. 2021;49:490 • In vitro binding experiments using 16 test drugs, showed no positively charged, neutral, or zwitterionic drugs bound to veverimer • Three negatively charged drugs (furosemide, aspirin, ethac

  13. Slide 13: Veverimer Manufacturing

    13 Veverimer Manufacturing • Veverimer drug substance (poly[allylamine-co-N,N′-diallyl-1,3-diaminopropane-co-1,2-diaminoethane]) is a free- flowing powder composed of low-swelling polymeric beads • Drug substance is manufactured at Patheon Austria GmbH & Co KG (Patheon) using a 2-step process at cur

  14. Slide 14: Veverimer Intellectual Property

    14 Veverimer Intellectual Property • Veverimer was discovered by Tricida utilizing its own proprietary technology • Tricida’s patent portfolio includes 233 patents in 52 different countries, including – compositions-of-matter – dosage unit forms – methods-of-treatment – medical use – methods of manu

  15. Slide 15: Veverimer Clinical Development Program Overview

    15 Veverimer Clinical Development Program – Overview VALOR-CKD was initially designed as a confirmatory postmarketing trial to verify and describe the clinical benefit of veverimer on CKD progression under the FDA”s Accelerated Approval Program. Safety and Efficacy Trials – Effect on Serum Bicarbona

  16. Slide 16: VALOR-CKD Pivotal Trial Summary

    16 VALOR-CKD Pivotal Trial Summary

  17. Slide 17: The VALOR-CKD Trial Design Overview

    17 The VALOR-CKD Trial Design Overview • Time-to-event, multicenter, randomized, double-blind, placebo-controlled trial • Primary endpoint: DD40, defined as time to first occurrence of renal death, ESRD or a confirmed ≥ 40% reduction in eGFR Veverimer QD (N = 741) Placebo QD (N = 739)Tr ea tm en t T

  18. Slide 18: VALOR-CKD Patient Disposition

    18 VALOR-CKD Patient Disposition 741 assigned to veverimer 739 assigned to placebo 143 discontinued study 105 death 23 withdrawal of consent 10 lost to follow-up 5 other598 completed Part B of the study 741 received veverimer 738 received placebo 5,245 patients assessed for eligibility 3,048 exclude

  19. Slide 19: VALOR-CKD Demographics and Baseline Characteristics

    19 VALOR-CKD Demographics and Baseline Characteristics Were Well-Balanced between Treatment Arms Parameter Veverimer N = 741 Placebo N = 739 Mean age (SD) – years 65.0 (11.87) 65.2 (12.30) Male – N (%) 433 (58.4) 421 (57.0) Mean eGFR (SD) – mL/min/1.73m2 29.2 (6.35) 29.1 (6.33) Mean serum bicarbonat

  20. Slide 20: Veverimer Safety Profile in the VALOR-CKD Trial Part B

    20 Veverimer Demonstrated an Excellent Safety Profile in the VALOR-CKD Trial Part B Veverimer (N=739) Placebo (N=737) Subjects with All-cause Death 105 (14.2%) 103 (14.0%) Subjects with Cardiovascular Death 42 (5.7%) 44 (6.0%) Subjects with Serious Adverse Events 197 (26.7%) 205 (27.8%) Subjects wit

  21. Slide 21: VALOR-CKD Did Not Meet Its Primary Endpoint

    21 VALOR-CKD Did Not Meet Its Primary Endpoint • Hazard ratio = 0.99 [95% CI, 0.78, 1.24; (p=0.898)] over the 26.7 months median duration of treatment Veverimer (N = 739) Placebo (N = 737) Hazard Ratio (95% CI) p-value Number (%) of Patients with Primary Endpoint Event 149 (20.2%) 148 (20.1%) 0.99 0

  22. Slide 22: VALOR-CKD Randomized Withdrawal Design

    22 VALOR-CKD Was Designed to Generate Acidotic and Non-acidotic Groups Using a Randomized Withdrawal Design Part B: Double-blind Veverimer or PlaceboPart A: Single-blind Veverimer Veverimer 67% of subjects randomized into Part B

  23. Slide 23: Unexpected Serum Bicarbonate Results in VALOR-CKD

    23 In the VALOR-CKD Trial, the Veverimer and Placebo Groups Demonstrated Unexpected Serum Bicarbonate Results • In Part A, the average increase in serum bicarbonate was 5.9 mEq/L, increasing from 17.5 mEq/L to 23.4 mEq/L • In Part B: ‒ The average serum bicarbonate over months 3 to 12 was: Veverimer

  24. Slide 24: VALOR-CKD Inconsistent with TRCA-101 and TRCA-301/301E

    24 VALOR-CKD Inconsistent with TRCA-101 and TRCA-301/301E In Prior Trials, Serum Bicarbonate Dropped Toward Baseline w/in 2 Weeks of Stopping Treatment 0 1 2 4 6 8 10 12 14 16 20 24 28 34 40 46 52 54 Weeks since Randomization Se ru m B ic ar bo na te (m Eq /L ; M ea n ± SE ) Veverimer Placebo End of

  25. Slide 25: ~60% of Placebo Subjects Had Serum Bicarbonate >20 mEq/L

    25 In the VALOR-CKD Trial ~60% of Placebo Subjects Had Serum Bicarbonate >20 mEq/L for the First 30+ Months of the Trial • At each of the 3-month timepoints between Month 3 and Month 30 in Part B, approximately 60% of the patients in the placebo group had a level of serum bicarbonate > 20 mEq/L (i.e

  26. Slide 26: Potential Alternatives for Future Development of Veverimer Post-VALOR-CKD

    26 Potential Alternatives for Future Development of Veverimer for the Treatment of Metabolic Acidosis Post-VALOR-CKD

  27. Slide 27: Interpretation of the Negative VALOR-CKD Primary Endpoint Results

    27 Interpretation of the Negative VALOR-CKD Primary Endpoint Results to Facilitate Design of a Potential New Outcomes Trial in Chronic Metabolic Acidosis • The difference in serum bicarbonate levels between the active and placebo treatment groups was insufficient to evaluate the effect of veverimer

  28. Slide 28: Post-Hoc Analysis of the VALOR-CKD Trial

    28 Post-Hoc Analysis of the VALOR-CKD Trial Illustrative Example of Veverimer and Placebo Subgroups Which Yields a 3 – 4 mEq/L Serum Bicarbonate Separation * Subgroup analysis was not part of pre-specified statistical analysis plan in the VALOR-CKD trial and is solely intended to inform potential al

  29. Slide 29: Potential Alternative Renal Outcomes Trial Design

    29 Potential Alternative Renal Outcomes Trial Design Placebo run-in to ensure that patients have stable chronic metabolic acidosis Veverimer QD Placebo QDTr ea tm en tSubjects with serum bicarbonate of 12 – 20 mEq/L, eGFR of 20 – 40 ml/min/1.73m2 Screening 3-Month, Single- Blind Placebo Treatment Pe

  30. Slide 30: Relationship between Serum Bicarbonate and Risk of DD40

    30 Relationship between Serum Bicarbonate and Risk of DD40 Data from VALOR-CKD Demonstrate an Association Between Higher Serum Bicarbonate and Lower DD40 Risk* • Although not an objective of the VALOR-CKD study protocol, the relationship between serum bicarbonate levels and the primary endpoint (DD4

  31. Slide 31: Illustrative Sample Size Calculation

    31 Illustrative Example of Sample Size Calculation Based on VALOR-CKD Data and the Observed Relationship between Serum Bicarbonate and DD40 • Illustrative sample size assumptions – Placebo event rate = 9.6% per year – Hazard ratio = 0.723 (derived from relationship between serum bicarbonate and DD40

  32. Slide 32: VALOR-CKD Data Related to Physical Function

    32 VALOR-CKD Data Related to Physical Function • No significant effects of veverimer were observed on the two secondary endpoints that assessed physical function (in contrast to results from the TRCA-301E study) – Change from baseline to Month 12 in the total score of the KDQOL physical function dom

  33. Slide 33: Alternative Development Opportunities

    33 Alternative Development Opportunities

  34. Slide 34: Alternative Research Directions for Veverimer

    34 Alternative Research Directions for Veverimer Metabolic Acidosis Is Implicated in a Number of Serious Conditions Indication / Setting Comments Peritoneal Dialysis + Hemodialysis  25% of peritoneal dialysis and 40% of hemodialysis patients have serum bicarbonate levels <22mEg/L (recommended 24-26

  35. Slide 35: Metabolic Acidosis in Peritoneal Dialysis and Hemodialysis

    35 Alternative Research Directions for Veverimer Management of Metabolic Acidosis in Patients Receiving Peritoneal Dialysis and Hemodialysis • Clinical practice guidelines recommend measuring of serum bicarbonate levels in maintenance dialysis patients and treating them to maintain a serum bicarbona

  36. Slide 36: Acidosis in Proximal and Distal Renal Tubular Acidosis

    36 Alternative Research Directions for Veverimer Management of Acidosis in Patients with Proximal and Distal Renal Tubular Acidosis (RTA) • Renal tubular acidosis is caused by a defect in the nephrons that either causes bicarbonate to be wasted at a lower- than-normal tubular maximum for bicarbonate

  37. Slide 37: Muscle and Bone Disorders in Patients with CKD

    37 Alternative Research Directions for Veverimer Treatment of Muscle and Bone Disorders in Patients with CKD, Low Bicarbonate Levels and Osteoporosis/Sarcopenia • Metabolic acidosis in CKD is associated with abnormalities in bone and muscle function in animal models and clinical studies • TRCA-301E

  38. Slide 38: Osteopenia/Osteoporosis in Post-menopausal Women and Men

    38 Alternative Research Directions for Veverimer Treatment of Osteopenia/Osteoporosis in Post-menopausal Women and Men with Osteopenia • Treatment with potassium citrate (an alkali salt) has been shown to improve bone mineral density and bone architecture and to reduce fracture risk scores in older

  39. Slide 39: Management of Patients with Kidney Stones

    39 Alternative Research Directions for Veverimer Management of Patients with Kidney Stones • Increasing serum bicarbonate lowers urinary calcium excretion and reduces the risk of recurrent calcium oxalate kidney stone formation – Potassium citrate is a current treatment • Alkalinization of urine is

  40. Slide 40: Stage 5 CKD as a Bridge to Dialysis

    40 Alternative Research Directions for Veverimer Management of Metabolic Acidosis in Patients with Stage 5 CKD as a “Bridge to Dialysis” • Uncontrolled acidosis is an indication for initiating dialysis. Acidosis often becomes markedly worse as patients approach eGFRs at which dialysis is typically i

  41. Slide 41: Slowing CKD Progression in Stage 2-3a CKD with Normal Serum Bicarbonate

    41 Alternative Research Directions for Veverimer Slowing CKD Progression in Patients with Stage 2 – 3a CKD and Normal Serum Bicarbonate • Published literature suggests that patients with CKD retain acid, even at early stages of the disease at a time when compensatory mechanisms have been able to mai

  42. Slide 42: Oncology Indications

    42 Alternative Research Directions for Veverimer Oncology indications • Acidosis may be a target in cancer treatment • In vitro studies in various cancer models have shown relationships between extracellular acidosis and tumor growth – In pancreatic adenocarcinomas, a metastatic phenotype is associa

Tricida — Corporate Update (November 2022) on 6ix